# Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

> **NCT01144663** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2095 (actual)

## Conditions studied

- Infections, Meningococcal
- Meningococcal Vaccines

## Interventions

- **BIOLOGICAL:** Nimenrix™
- **BIOLOGICAL:** Menjugate®
- **BIOLOGICAL:** NeisVac-CTM
- **BIOLOGICAL:** Infanrix™ hexa
- **BIOLOGICAL:** Synflorix™

## Key facts

- **NCT ID:** NCT01144663
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2012-06-22
- **Final completion:** 2013-09-10
- **Target enrollment:** 2095 (ACTUAL)
- **Last updated:** 2020-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144663, "Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01144663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*